AstraZeneca coronavirus vaccine authorized by WHO

By The Science Advisory Board staff writers

February 16, 2021 -- The World Health Organization (WHO) has granted an emergency use listing for AstraZeneca's coronavirus vaccine, paving the way for distribution in Africa soon.

Authorization was granted for the product -- dubbed Covishield -- to AstraZeneca and the Serum Institute of India through a sublicensing agreement for global manufacturing and supply. Per the WHO, the product should be given in two doses, with an interval of from eight to 12 weeks, with distribution focused on countries where the new coronavirus variants, such as B1.351 in South Africa, have become problematic.

AstraZeneca is providing the product at cost. In a statement, the Serum Institute of India said that it plans to start deliveries to African and other low- and middle-income countries immediately.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here